Table 1.

Clinical trials investigating new treatments to overcome ICI resistance in NSCLC.

Intervention/treatment	Drug	ClinicalTrials.gov Identifier	Phase	Patients	Recruitment Status
Vaccines
	RO7198457	NCT03289962	I	ICI-naiıve and pretreated	Active, not recruiting
	Viagenpumatucel-L	NCT02439450	I/II	Including ICI-pretreated	Completed
	Autologous LN-145	NCT04614103	II	Documented PD after ICI-pretreated	Recruiting
	STEMVAC	NCT05242965	II	ICI-pretreated	Recruiting
Adoptive cell therapy
	Letetresgene Autoleucel T-cells	NCT03709706	I/II	Including ICI-pretreated	Terminated
Targeting-drive gene
	Cabozantinib (c-MET)	NCT03600701	II	ICI-naive and pretreated	Recruiting
	Cobimetinib(MEK)	NCT03170960	I/II	ICI-naive and pretreated	Active, not recruiting
	SAR408701(anti-CEACAM5)	NCT04394624	II	Having PD after ICI/chemotherapy-pretreated	Recruiting
Anti-angiogenic agents
	Cabozantinib	NCT04471428	III	Documented PD after previous ICI treatment	Active, not recruiting
	Sitravatinib	NCT03906071	III	Prior treatment with ICI and chemotherapy	Active, not recruiting
	Lenvatinib	NCT03976375	III	Documented PD after previous ICI treatment	Active, not recruiting
	Nintedanib	NCT03377023	I/II	ICI-naive and pretreated with chemotherapy, ICI, or targeted therapy	Active, not recruiting
	Ramucirumab	NCT03689855	II	ICI-pretreated	Active, not recruiting
		NCT04340882	II	Having PD after ICI+chemotherapy	Recruiting
TME modulators
	Bintrafusp Alfa(anti- TGF-β)	NCT04396535	II	ICI+chemotherapy-pretreated	Active, not recruiting
	Entinostat (anti-HDAC)	NCT01928576	II	ICI-naiıve and pretreated	Active, not recruiting
	Mocetinostat(anti-HDAC)	NCT02954991	II	ICI-pretreated	Completed
	Vibostolimab (anti-TIGIT)	NCT04725188	II	Having PD after Chemotherapy and ICI	Active, not recruiting
	Abemaciclib(anti-CDK4/6)	NCT02779751	I	ICI-naive and pretreated	Active, not recruiting